article thumbnail

Regeneron bispecific approved for myeloma; Concentra to buy IGM

Bio Pharma Dive

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Antibody 242
article thumbnail

ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study

Pharmaceutical Technology

First-in-human data for the trispecific antibody suggest a paradigm shift for the relapsed/refractory multiple myeloma space.

Antibody 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody

pharmaphorum

AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers

article thumbnail

Triggering Bacterial Calcification to Combat MRSA

Scienmag

By inducing bacterial calcification through a sophisticated antibody-polysialic acid conjugate, researchers have demonstrated not only potent antibacterial activity against MRSA but also an intriguing capacity to modulate the host immune system, opening new horizons for combating drug-resistant pathogens. aureus , with polysialic acid (PSA).

article thumbnail

Recast CDC panel recommends new RSV antibody for infants

Bio Pharma Dive

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

Antibody 152
article thumbnail

Biogen shows its IgAN hand with felzartamab data

pharmaphorum

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies for the disorder.Data reported at the Kidney Week 2024 congress in San Diego showed that felzartamab was able to achieve "substantial" reductions in proteinuria (..)

Antibody 114
article thumbnail

Celltrion’s Avtozma Receives FDA Approval, Making it the Third Actemra Biosimilar to Hit the Market

XTalks

That was followed by a full approval for the same patient subset in December 2022, making it the first FDA-approved monoclonal antibody to treat COVID-19. In June 2021, the FDA granted emergency use authorization (EUA) for Actemra to treat hospitalized COVID-19 patients. It also has EUA for children aged between two and 18.